Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial

Xiaoqiang Liu(Yunnan Center for Disease Control And Prevention), Jinzhong Lin(Fudan University), Zhongfang Wang(First Affiliated Hospital of Guangzhou Medical University), Xiaoyun Yang(Shandong University), Lorenz von Seidlein(Angkor Hospital for Children), Yangyang Qi(Fudan University), Jing Lü(Center for Drug Evaluation and Research), Lin Yuan(Vir Biotechnology (Switzerland)), Hong Su(Anhui University of Science and Technology), Xuanyi Wang(Yangzhou University), M M Zhao(Huaian First People’s Hospital), Yanxiang Zou(Yunnan Center for Disease Control And Prevention), Jun Dai(Shanghai Customs College), Weimin Gao(University of North Florida), Yanxia Wang(Southwest Forestry University), Wei Li(Institute of Zoology), Jingjing Chen(Kunming Medical University), Zhihua Zhang(Taiwan Centers for Disease Control), Jianchang He(Huaian First People’s Hospital), Tao Huang(Westlake University), Feng Shi(Taiwan Centers for Disease Control), Xiaozhong Li(Taiwan Centers for Disease Control), Jiandong Zheng(Xian Center for Disease Control and Prevention), Lili Huang(Henan Provincial Center for Disease Control and Prevention), Xiu-Liang Yang(First Affiliated Hospital of Guangzhou Medical University), Zhiwei Jiang(Statistical Research (United States)), De-Fang Dai(Hunan Provincial Center for Disease Control and Prevention), Zhifei Zhan(Hohai University), Xuemei Yan(Fudan University)
Human Vaccines & Immunotherapeutics
May 16, 2025
Cited by 1


Related Papers